ADOPT (A Diabetes Outcomes Prevention Trial) showed that initial treatment with just rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. In CJASN, we examine the differences in albumin excretion, renal function and blood pressure over the course of 5 years between the treatment groups....
[Read more...]The ADOPT study (A Diabetes Outcomes Prevention Trial) showed that treatment with rosiglitazone alone provided somewhat more effective glycaemic control than metformin or glyburide alone, in patients with recently diagnosed type 2 diabetes. In a paper published recently in Diabetes, we examined changes in β-cell function and insulin sensitivity among the three treatments in ADOPT....
[Read more...]Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial).
Steven E....
Selected slides from the ADOPT plenary session at the IDF World Diabetes Congress 2006 available
[Link]The ADOPT results were announced at the IDF 19th World Diabetes Congress and simultaneously published in the New England Journal of Medicine.
[Link]Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe
Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI; ADOPT Study Group
Diabetes 2004;53:3193-3200
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Viberti,G; Kahn,SE; Greene,DA; Herman,WH; Zinman,B; Holman,RR; Haffner,SM; Levy,D; Lachin,JM; Berry,RA; Heise,MA; Jones,NP; Freed,MI
Diabetes Care....